Untitled Document
Massachusetts  Press Release Distribution
Home Page
Submit Press Release
EPR Nationwide Sites
PR Agencies in Massachusetts
Browse By Industries
Search Press Releases
About EPR
Help Pages
Contact Us
Disclaimer
Privacy Policy
TOS
 
 
 
(MA) Accounting
(MA) Advertising
(MA) Aerospace
(MA) Agriculture
(MA) Apparel & Fashion
(MA) Automotive
(MA) Biotech
(MA) Chemicals
(MA) Computers
(MA) Construction
(MA) Consumer Services
(MA) Defense
(MA) E ducation
(MA) Electronics
(MA) Energy
(MA) Entertainment
(MA) Environment
(MA) Financial
(MA) Food & Beverage
(MA) Government
(MA) Healthcare
(MA) Human Resources
(MA) Industrial
(MA) International Trade
(MA) Internet & Online
(MA) Law
(MA) Management
(MA) Marketing
(MA) Media
(MA) Non Profit
(MA) Pharmaceuticals
(MA) Real Estate
(MA) Retail
(MA) Semiconductors
(MA) Small Business
(MA) Software
(MA) Telecom
(MA) Transportation / Logistics
 

EPR in Social Media Sites

EPR at Digg
EPR at Del.icio.us
EPR at NosyJoe
EPR at LinkedWords
EPR at Yahoo MyWeb
EPR at Furl
EPR at Mixx

EPR Blog in Blog Search Engines

EPR Blog in Google's BlogSearch
EPR Blog at Technorati

EPR in News Aggregators

EPR in Google's News

 

EPR Archived News

Archived News 2008
~ December
~ November
~ October
~ September
~ August

~ July

~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2007
~ December
~ November
~ October
~ September
~ August

~ July

~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2006
~ December
~ November
~ October
~ September
~ August
~ July

~ June
~ May
~ April
~ March
~ February
~ January


Archived News 2005
~ December
~ November
~ October
~ September
~ August
~ July
~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2004
~ December
~ November
~ October
~ September
~ August
~ July

 

 
LinkedWords - Helping web sites get contextually linked each other

 

 

 

GENFIT initiates Phase II clinical trials with GFT14

Released on = May 2, 2006, 7:28 am

Press Release Author = Milestones

Industry = Biotech

Press Release Summary = Phase I results revealed very good tolerance in healthy volunteers as well as an excellent security profile for GFT14, one of the medical candidates that GENFIT is developing to tackle cardiometabolic risk.

Press Release Body = Lille (France), Cambridge (Massachusetts), 2nd May 2006 – GENFIT, the biopharmaceutical company engaged in the discovery and development of medical candidates in the areas of cardiovascular, inflammatory and metabolic diseases, today announced the entry into Phase II clinical trials of GFT14, destined for the treatment of cardiometabolic risk.

The decision to commence Phase II was taken in light of the excellent results obtained during the Phase I. Initiated in March 2005, this test was carried out on over one hundred healthy volunteers who ingested GFT14 either in a single dose (50 – 500mg) or in a repeated dose over fourteen days (50 – 300 mg/day).

The results demonstrated that GFT14 attained all of its principal objectives; namely, that no significant adverse effect was registered during the course of the trials; that any reported adverse effect was weak, (and without the implication of the treatment being proven); that GFT14 is very well absorbed with pharmacokinetic parameters being perfectly compatible with a single daily dose. The trials in a healthy volunteer therefore concluded that GFT14 is very well tolerated.

“This first phase of clinical trials proved that the innovative formulation of GFT14 developed by GENFIT produced a very good margin of security”, commented Professeur Fruchart, who continued : “ Fresh from these promising results, an initial Phase II study targeting the effectiveness of GFT14 in patients with dyslipidemia has just been undertaken. The first patient should begin tests later this month, with results expected at the beginning of 2007” .

GFT14, a proprietary compound from GENFIT, is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides) and on other risk factors such as hypertension or diabetes. Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based). The risks of medical interaction are weak and GFT14 may be easily combined with statins or other antidiabetic molecules (glitazones).

Dyslipidemic patients are defined as having a high level of “bad” cholesterol (LDL-C) and/or triglycerides and/or a low level of good cholesterol (HDL-C). They have, therefore, an increased risk of developing atherosclerosis, the clinical complications of which pose serious health problems, especially in cases of coronary implication.


Jean-François MOUNEY, Chairman and CEO of GENFIT declared:

“ These highly promising results confirm the hypothesis that GFT14 constitutes, thanks to its novel pharmacological approach, a significant advance in the treatment of metabolic disorders. The results announced today illustrate our capacity to deliver innovative therapeutic solutions with huge potential and further reinforce the value of our product portfolio, currently comprising seventeen research
programmes of which nine molecules are in development. Genfit is engaged in challenging the soaring global cardiometabolic pandemic characterized by obesity, diabetes and cardiovascular illness which are affecting an increasingly younger population.”

About GENFIT

The emerging biopharmaceutical company, GENFIT (www.genfit.com) studies gene deregulation, which is at the origin of some of the most wide-spread diseases. The GENFIT group identifies new therapeutic targets and develops drug candidates. Its most advanced programs, conducted internally or in partnership with industry leaders such as SANOFI - AVENTIS, PIERRE FABRE, SOLVAY - FOURNIER, MERCK AG, UCB, KOWA, SERVIER, concentrate on the treatment of key metabolic and inflammatory disorders. GENFIT’s initial proprietary medicines will concentrate on global cardiovascular risk by treating several pathologies, such as atherosclerosis, diabetes and obesity, simultaneously with a single molecule. Founded and managed by Professeur Jean-Charles FRUCHART and Mr. Jean-François MOUNEY, the company is headquartered in Lille with facilities in Cambridge (USA). The company currently employs over 110 people.


– END –




Web Site = http://www.genfit.com

Contact Details = Contacts

GENFIT :
Jean-François MOUNEY, Chairman and CEO
Kate PORTER, Corporate Communications Manager
Phone : +33 (0) 3 20 16 40 11
Phone : +33 (0) 3 20 16 40 79

MILESTONES – Press Relations
Bruno ARABIAN
Phone : +33 (0) 1 70 08 04 13 / +33 (0) 6 87 88 47 26

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •  

     

     

    Untitled Document

     

    Submit Press Release (Free)Submit Press Release

     

    Press Release ForumPress Release Forum

     

    Press Release BlogPress Release Blog

     

     

     

     

     

    Untitled Document

    Submit to EPRSubmit to EPRSubmit to DiggSubmit to DiggSubmit to RedditSubmit to Reddit NosyJoe - The Social Search EngineSubmit to NosyJoe

    About | Submit Press Release | Help | Search | Links | Nationwide / EPR Network

    © 2004-2008 Massachusetts-Press-Release.com. Part of EPR-Network.com. All Rights Reserved. All trade marks and names are owned by their respective owners
    Link to Us / Privacy / Disclaimer / Feedback -- Questions, Suggestions, Comments at E-mail: info@EPR-Network.com
    EPR disclaims any content found in press releases -- full disclaimer can be found here

    Contextually linked in LinkedWords

     

     
    Massachusetts Press Release Distribution
     
    EPR Network
    EPR Nationwide Network:

    EPP-Network.com
    Express-Press-Release.Net
    NewYork-Press-Release.com
    California-Press-Release.com

    Texas-Press-Release.com
    Florida-Press-Release.com
    Tennessee-Press-Release.com
    Washington-Press-Release.com

    Illinois-Press-Release.com
    Virginia-Press-Release.com
    Georgia-Press-Release.com
    Maryland-Press-Release.com

    Massachusetts-Press-Release.com
    Ohio-Press-Release.com
    PressReleaseForum.com

    EPR Blog Network:

    EprNetworkBlog.com
    Web 2.0 Innovations & News
    EPRSoftwareNews.com
    EPRTelecomNews.com
    EPRInternetNews.com
    EPRComputerNews.com
    EPRTransportationLogisticsNews.com
    EPRAutomotiveNews.com
    EPRIndustrialNews.com
    EPRFoodBeverageNews.com
    EPRElectronicsNews.com

    EPRFinancialNews.com
    EPRRetailNews.com
    EPRRealEstateNews.com
    EPRConstructionNews.com
    EPRLawNews.com
    EPRAccountingNews.com
    EPRSmallBusinessNews.com
    EPRManagementNews.com
    EPRHumanResourcesNews.com

    EPREntertainmentNews.com
    Fashion-Talk.com
    EPRTravelNews.com
    EPRSportNews.com
    EPRAdvertisingNews.com
    EPRMediaNews.com
    EPRMarketingNews.com
    EPRConsumerNews.com

    EPRHealthcareNews.com
    EPREnvironmentNews.com
    EPREnergyNews.com
    EPRNonProfitNews.com
    EPREducationNews.com
    EPRGovernmentNews.com
    EPRBiotechNews.com
    EPRAerospaceNews.com
    EPRDefenseNews.com

    EPR @ Social Media and News Aggregators:

    EPP Network @ Google News
    EPP Network @ Digg
    EPP Network @ Mixx
    EPP Network @ Facebook

    EPP Network @ Technorati
    EPP Network @ Del.icio.us
    EPP Network @ Yahoo MyWeb

    EPP Network @ LinkedWords
    EPP Network @ NosyJoe
    EPP Network @ NosyJoe /.net

    EPP Network @ Feedburner
    EPP Network @ Twitter
    EPP Network @ Furl